R&D Focusing too many R&D resources on one drug: The hidden cost... Drug development is a high-stakes, high-cost endeavour.
Events Partner Content 13th Annual Pharma Resource Planning and Portfolio Managemen... Prioritizing Projects with Tools, Data, and Governance
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
